Literature DB >> 6295896

A pharmacological approach to the inhibition of platelet adhesion and platelet aggregation. Wright-Schulte Lecture.

M Verstraete.   

Abstract

A first level of pharmacological interference with platelet function is located at the site of the agonist-receptor interaction (receptors for collagen, adenosine diphosphate, serotonin, fibrinogen). A second level of interaction is to prevent the mobilization of intracellular calcium ions which can be obtained by inhibition of phosphodiesterase, activation of cAMP (e.g. with prostacyclin analogues), inhibition of thromboxane A2 formation or blocking of its receptors. Compounds preventing the platelet contractile process or platelet secretion could theoretically also prevent some platelet functions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6295896     DOI: 10.1159/000214690

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  3 in total

Review 1.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

2.  Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Differential inhibitory effects of isosorbide dinitrate and its mononitrate metabolites on platelet aggregation and thromboxane formation.

Authors:  P H Rolland; J Sampol; B Lacarelle; D Arnoux; F Leca; E Gueydon; J P Cano
Journal:  Pharm Res       Date:  1985-03       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.